Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats ...
Ivabradine is indicated by the FDA to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction ≤35%, who are in sinus rhythm with resting heart rate ≥70 beats per minute and either are on maximally tolerated doses of beta-blockers or have a contrain...
Cardiology office, Rheinfelden, Argovia, Switzerland
Policlinico Casilino, Rome, Italy
Chair of Cardiology Second University of Naples, Naples, Italy
Chair of Cardiology Second Univesity of Naples, Naples, Italy
Chair of Cardiology, Naples, Italy
Department of Medicine III of the University Clinics Halle (Saale) of the Martin-Luther-University Halle-Wittenberg, Halle (Saale), Saxony-Anhalt, Germany
Centre for Clinical and Basic Research - IRCCS San Raffaele, Roma, Italy
IRCCS San Raffaele, Roma, Italy
Bern University Hospital, Bern, Switzerland
G. B. Pant Hospital, New Delhi, Delhi, India
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.